REFERENCES
1. Bavaro D.F., Diella L., Fabrizio C., et al. Peculiar clinical presentation of COVID-19 and predictors of mortality in the elderly: a multicentre retrospective cohort study. Int J Infect Dis. 2021; 105: 709–15. DOI: https://doi.org/10.1016/j.ijid.2021.03.021
2. Erdal G.S., Polat O., Erdem G.U., et al. The mortality rate of COVID-19 was high in cancer patients: a retrospective single-center study. Int J Clin Oncol. 2021; 26 (5): 826–34. DOI: https://doi.org/10.1007/s10147-021-01863-6
3. Bavaro D.F., Fiordelisi D., Angarano G., et al. Targeted therapies for autoimmune/idiopathic nonmalignant diseases: risk and management of opportunistic infections. Expert Opin. Drug Saf. 2020; 19 (7): 817–42. DOI: https://doi.org/10.1080/14740338.2020.1767585
4. Ronco C., Reis T., Husain-Syed F. Management of acute kidney injury in patients with COVID-19. Lancet Respir Med. 2020; 8 (7): 738–42. DOI: https://doi.org/10.1016/S2213-2600(20)30229-0
5. Wang F., Ao G., Wang Y., et al. Risk factors for mortality in hemodialysis patients with COVID-19: a systematic review and meta-analysis. Ren Fail. 2021; 43 (1): 1394–407. DOI: https://doi.org/10.1080/0886022X.2021.1986408
6. Chen C.Y., Shao S.C., Chen Y.T., et al. Incidence and clinical impacts of COVID-19 infection in patients with hemodialysis: systematic review and meta-analysis of 396,062 hemodialysis patients. Healthcare (Basel). 2021; 9 (1): 47. DOI: https://doi.org/10.3390/healthcare9010047
7. Zubkin M.L., Frolova N.F., Kim I.G., et al. COVID-19 in haemodialysis patients: result analysis of the first year of the pandemic. Terapevticheskiy arkhiv [Therapeutic Archive]. 2021; 93 (11): 1325–33. DOI: https://doi.org/10.26442/00403660.2021.11.201215 (in Russian)
8. Coronavirus (COVID-19) up-date: FDA authorizes monoclonal antibodies for treatment of COVID-19. In: FDA News Release. November 21, 2020. URL: https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-monoclonal-antibodies-treatment-covid-19
9. Miguez-Rey E., Choi D., Kim S., et al. Monoclonal antibody therapies in the management of SARS-CoV-2 infection. Expert Opin Investig Drugs. 2022; 31 (1): 41–58. DOI: https://doi.org/10.1080/13543784.2022.2030310
10. Chigutsa E., O’Brien L., Ferguson-Sells L., et al. Population pharmacokinetics and pharmacodynamics of the neutralizing antibodies bamlanivimab and etesevimab in patients with mild to moderate COVID-19 infection. Clin Pharmacol Ther. 2021; 110 (5): 1302–10. DOI: https://doi.org/10.1002/cpt.2420
11. Fact Sheet for Health Care Providers Emergency Use Authorization (EUA) of Casirivimab and Imdevimab.
12. Fact Sheet for Health Care Providers Emergency Use Authorization (EUA) of Bamlanivimab.
13. Interim guidelines «Prevention, diagnosis and treatment of new coronavirus infection (COVID-19)». Version 11 (07.05.2021). Moscow, 2021. (in Russian)
14. Ranieri V.M., Rubenfeld G.D., Thompson B.T., et al. Acute respiratory distress syndrome: the Berlin Definition. JAMA. 2012; 307 (23): 2526–33. DOI: https://doi.org/10.1001/jama.2012.5669
15. Charlson M.E., Pompei P., Ales K.L., McKenzie C.R. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chron Dis. 1987; 40 (5): 373–83. DOI: https://doi.org/10.1016/0021-9681(87)90171-8
16. Verderese J.P., Stepanova M., Lam B., et al. Neutralizing monoclonal antibody treatment reduces hospitalization for mild and moderate coronavirus disease 2019 (COVID-19): a real-world experience. Clin Infect Dis. 2022; 74 (6): 1063–9. DOI: https://doi.org/10.1093/cid/ciab579
17. Vellas C., Del Bello A., Debardet A., et al. Influence of treatment with neutralizing monoclonal antibodies on the SARS-CoV-2 nasopharyngeal load and quasispecies. Clin Microbiol Infect. 2022; 28 (1): 139.e5–8. DOI: https://doi.org/10.1016/j.cmi.2021.09.008
18. van de Veerdonk F.L., Giamarellos-Bourboulis E., Pickkers P., et al. A guide to immunotherapy for COVID-19. Nat Med. 2022; 28 (1): 39–50. DOI: https://doi.org/10.1038/s41591-021-01643-9
19. Self W.H., Sandkovsky U., Reilly C.S., et al. Efficacy and safety of two neutralising monoclonal antibody therapies, sotrovimab and BRII-196 plus BRII-198, for adults hospitalised with COVID-19 (TICO): a randomised controlled trial. Lancet Infect Dis. 2022; 22 (5): 622–35. DOI: https://doi.org/10.1016/S1473-3099(21)00751-9
20. Alunno A., Najm A., Machado P.M., et al. 2021 update of the EULAR points to consider on the use of immunomodulatory therapies in COVID-19. Ann Rheum Dis. 2022; 81 (1): 34–40. DOI: https://doi.org/10.1136/annrheumdis-2021-221366
21. Baum A., Ajithdoss D., Copin R., et al. REGN-COV2 antibodies prevent and treat SARS-CoV-2 infection in rhesus macaques and hamsters. Science. 2020; 370 (6520): 1110–5. DOI: https://doi.org/10.1126/science.abe2402
22. Weinreich D.M., Sivapalasingam S., Norton T., et al. REGN-COV2, a neutralizing antibody cocktail, in outpatients with COVID-19. N Engl J Med. 2021; 384 (3): 238–51. DOI: https://doi.org/10.1056/NEJMoa2035002
23. Bartoletti M., Azap O., Barac A., et al. ESCMID COVID-19 living guidelines: drug treatment and clinical management. Clin Microbiol Infect. 2022; 28 (2): 222–38. DOI: https://doi.org/10.1016/j.cmi.2021.11.007
24. Dougan M., Nirula A., Azizad M., et al. Bamlanivimab plus etesevimab in mild or moderate COVID-19. N Engl J Med. 2021; 385 (15): 1382–92. DOI: https://doi.org/10.1056/NEJMoa2102685
25. Taylor P.C., Adams A.C., Hufford M.M., et al. Neutralizing monoclonal antibodies for treatment of COVID-19. Nat Rev Immunol. 2021; 21 (6): 382–93. DOI: https://doi.org/10.1038/s41577-021-00542-x
26. Falcone M., Tiseo G, Valoriani B., et al. Efficacy of bamlanivimab/etesevimab and casirivimab/imdevimab in preventing progression to severe COVID-19 and role of variants of concern. Infect Dis Ther. 2021; 10 (4): 2479–88. DOI: https://doi.org/10.1007/s40121-021-00525-4
27. Hoffmann M., Krüger N., Schulz S., et al. The Omicron variant is highly resistant against antibody-mediated neutralization: implications for control of the COVID-19 pandemic. Cell. 2022; 185 (3): 447–56. DOI: https://doi.org/10.1016/j.cell.2021.12.032